Is Selinexor an imported drug or a domestic drug and market situation analysis

Selinexor is an oral selective nuclear export inhibitor (SINE). It mainly inhibits the function of nuclear export protein XPO1 to block the abnormal transport of key tumor suppressor proteins in cancer cells, thereby exerting anti-tumor effects. As the world's first XPO1 inhibitor, selinesol has shown good efficacy in blood tumors such as multiple myeloma and diffuse large B cell lymphoma (DLBCL). At present, the drug has been officially approved for marketing in China and has been included in the national medical insurance directory, which has greatly reduced the financial burden for patients who require long-term treatment.

In terms of market positioning, Selinisol is an imported innovative drug developed by the American company Karyopharm . After it is launched in China, patients can purchase it directly through regular hospital and pharmacy channels. The price of original medicine is relatively high, ranging from 5,000 to more than 10,000 yuan per box. The cost will vary according to different specifications and treatment courses. Since this drug has been included in the scope of medical insurance reimbursement, eligible patients can enjoy a certain percentage of cost reduction. For specific reimbursement information, you need to consult the medical insurance department of the hospital where you are located.

In addition to domestic original drugs, generic drugs of selinexol have also appeared in overseas markets, among which the Lao version of the generic drug is more common. The ingredients of the Lao version of selinexol are basically the same as those of the domestic original drug, but it has a clear advantage in price, with each box costing only more than 2,000 yuan. This price gap can significantly reduce the treatment burden for patients with limited financial conditions and long-term need for medication, and therefore has attracted attention among some patient groups.

Overall, Seleniso’s accessibility in the domestic market is gradually improving. Patients can either choose imported original drugs reimbursed by medical insurance, or obtain overseas generic drugs through formal channels under the guidance of doctors, thereby finding a balance between efficacy and economy. With the deepening of clinical application, selinesol is expected to further expand its indications and benefit more patients with hematological tumors. For patients, standardizing the purchase of medicines and following doctor's instructions for treatment are the keys to ensuring efficacy and safety.

Reference link:https://www.drugs.com